Drug discovery and development with plant-derived compounds

Progress in Drug Research

Volumn 65, Issue , 2008, Pages 46-118

  Potterat, Olivier ^a   Hamburger, Matthias ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPHENINE; ALKALOID; AMPROTROPINE; ANTINEOPLASTIC AGENT; ARTEMISININ; ATROPINE METHYL NITRATE; CAMPTOTHECIN; CANNABIS; DIAMORPHINE; DOCETAXEL; ELLIPTICINE; ELLIPTINIUM ACETATE; GLYCOPROTEIN P; IDN 5180; MORPHINE; NAVELBINE; ORTATAXEL; PACLITAXEL; SCOPOLAMINE BUTYL BROMIDE; TAXOPREXIN; TIOTROPIUM BROMIDE; TOPOTECAN; TROPANE ALKALOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VINBLASTINE SULFATE; VINCRISTINE SULFATE; VINDESINE; VINFLUNINE; ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; DRUG; IMMUNOLOGICAL ADJUVANT; NEUROPROTECTIVE AGENT; PLANT MEDICINAL PRODUCT;

ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARCANUM; ATHEROSCLEROSIS; BIODIVERSITY; BLADDER DISEASE; BREAST CANCER; CATHARANTHUS ROSEUS; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLON CANCER; CORONARY ARTERY DISEASE; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROXYLUM COCA; ERYTHROXYLUM NOVOGRANATENSE; ETHNOPHARMACOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFLAMMATORY DISEASE; LEUKEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; MALARIA; MEDICINAL PLANT; METABOLIC DISORDER; NEOPLASM; NOCICEPTION; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PAIN; PAPAVER SOMNIFERUM; PRIORITY JOURNAL; REVIEW; STOMACH SPASM; TAXUS BREVIFOLIA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; ISOLATION AND PURIFICATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIVIRAL AGENTS; CARDIOVASCULAR AGENTS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; PHARMACEUTICAL PREPARATIONS; PLANT PREPARATIONS; PLANTS, MEDICINAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38449106795     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7643-8117-2_2     Document Type: Review

References (204)

1. Huffman MA (1997) Current evidence for self-medication in primates: A multidisciplinary perspective. Yearbook Phys Anthropol 40: 171-200
2. Krief S, Huffman MA, Sevenet T, Hladik CM, Grellier P, Loiseau PM, Wrangham RW (2006) Bioactive properties of plants ingested by chimpanzees (Pan troglodytes schweinfurthii) in the Kibale National Park, Uganda. Am J Primat 68: 51-71
3. Sneader W (2005) Drug discovery - a history. Wiley, Chichester
4. Hesse M (2000) Alkaloide - Fluch oder Segen der Natur? Verlag Helvetica Chimica Acta, Zürich, 322
5. Harvey AL (2002) Natural products for high-throughput screening. In: MM Iwu, JC Wootton (eds): Ethnomedicine and drug discovery, Elsevier, Amsterdam, 39-44
6. Sneader W (1996) Drug prototypes and their exploitation. Wiley, Chichester, 3-10
7. Hamburger M, Marston A, Hostettmann K (1991) Search for new drugs of plant origin. Advances in Drug Research vol. 20, Academic Press Ltd, 167-215
8. Farnsworth NR, Kaas CJ (1981) An approach utilizing information from traditional medicine to identify tumor-inhibiting plants. J Ethnopharmacol 3: 85-99
9. Hamburger M, Hostettmann K (1991) Bioactivity in plants: The link between phytochemistry and medicine. Phytochemistry 30: 3864-3874
10. Wolfender JL, Terreaux C, Hostettmann K (2000) The importance of LC-MS and LC-NMR in the discovery of new lead compounds from plants. Pharm Biol 38 (Suppl): 41-54
11. Wolfender JL, Ndjoko K, Hostettmann K (2003) Liquid chromatography with ultraviolet absorbance-mass spectrometric detection and with nuclear magnetic resonance spectrometry: A powerful combination for the on-line structural investigation of plant metabolites. J Chromatogr A 1000: 437-455
12. Bringmann G, Messer K, Wohlart M, Kraus J, Dumbuya K, Rückert M (1999) HPLC-CD on-line coupling in combination with HPLC-NMR and HPLC-MS/MS for the determination of the full absolute stereostructure of new metabolites in plant extracts. Anal Chem 71: 2678-2686
13. Niessen WMA, Lin J, Bondoux JC (2002) Developing strategies for isolation of minor impurities with mass spectrometry-directed fractionation. J Chromatogr A 970: 131-140
14. Reynolds WF, Enriquez RG (2002) Chosing the best pulse sequences, acquisition parameters, postacquisition processing strategies, and probes for natural product structure elucidation by NMR spectroscopy. J Nat Prod 65: 221-244
15. Potterat O, Hamburger M (2006) Natural products in drug discovery - concepts and approaches for tracking bioactivity. Curr Org Chem 10: 899-920
16. VanMiddlesworth F, Cannell RJP (1998) Dereplication and partial identification of natural products, In: RJP Cannell (ed.) In: Methods in Biotechnology, vol. 4, Natural Product Isolation, Human Press Inc, Totowa, New Jersey, 279-327
17. Bindseil K, Jakupovic J, Wolf D, Lavayre J, Leboul J, vand der Pyl D (2001) Pure compound libraries; a new perspective for natural product based drug discovery. Drug Discov Today 6: 840-847
18. Abel U, Koch C, Speitling M, Hanske FG (2002) Modern methods to produce natural-product libraries. Curr Opin Chem Biol 6: 453-458
19. Jia Q (2003) Generating and screening a natural product library for cyclooxygenase and lipoxygenase dual inhibitors. Stud Nat Prod Chem 29 (Bioactive Natural Products (Part J)): 643-718
20. Eldridge GR, Vervoort, HC, Lee CM, Cremin PA, Williams CT, Hart SM, Goering MG, O'Neil-Johnson M, Zeng L (2002) High-throughput method for the production and analysis of large natural product libraries for drug discovery. Anal Chem 74: 3963-3971
21. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnoparmacol 100: 72-79
22. Newmann DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66: 1022-1037
23. Butler MS (2005) Natural products to drugs: Natural product derived compounds in clinical trials. Nat Prod Rep 22: 162-195
24. Bennouna J, Campone M, Delord JP, Pinel MC (2005) Vinflunine: A novel antitubulin agent in solid malignancies. Expert Opin Inv Drug 14: 1259-1267
25. McIntyre JA, Castaner J (2004) Vinflunine: Antimitotic vinca alkaloid. Drug Future 29: 574-580
26. Wani MC, Taylor HL, Wall ME, Coggin P, McPhail AT (1971) Plant antitumor agents: VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327
27. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP (1993) Taxol; mechanisms of action and resistance. J Natl Cancer I Monogr 15: 55-61
28. Barboni L, Ballini R, Giarlo G, Appendino G, Fontana G, Bombardelli E (2005) Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390. Bioorg Med Chem Lett 15: 5182-5186
29. Beckers T, Mahboobi S (2003) Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy. Drug Future 28: 767-785
30. Dubois J, Guénard D, Guéritte F (2003) Recent development in antitumour taxoids. Expert Opin Ther Patents 13: 1809-1823
31. Ojima I, Geney R, Ungureanu IM, Li D (2002) Medicinal chemistry and chemical biology of new generation taxcane antitumor agents. Life 53: 269-274
32. Geney R, Chen J, Ojima I (2005) Recent advances in the new generation taxane anticancer agents. Med Chem 1: 125-139
33. Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F (2004) Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Brit J Cancer 90: 1464-1468
34. Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, M D'Incalci E, Bombardelli E, Morazzoni P et al (2003) IDN 5390: An oral taxane candidate for protracted treatment schedules. Brit J Cancer 88: 965-972
35. Jordan MA, Ojima I, Rosas F, Distefano M, Wilson L, Scambia G, Ferlini C (2002) Effects of novel taxanes SB-T-2113 and IDN5109 on tubulin polymerisation and mitosis. Chem Biol 9: 93-101
36. Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, Webb NL, Baker SD, Wolff AC, Donehower RC (2001) Tumor targeting by conjugation of DHA to paclitaxel. J Contr Rel 74: 233-236
37. Kuznetsova L, Chen J, Sun L, Wu X, Pepe A, Veith JM, Pera P, Bernacki R, Ojima I (2006) Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 16: 974-977
38. Stierle, A, Strobel G, Stierle D (1993) Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 260: 214-216
39. Auclair C (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259: 1-14
40. Lee K-H, Xiao Z (2003) Lignan in treatment of cancer and other diseases. Phytochem Rev 2: 341-362
41. Kluza J, Mazinghien R, Irwin H, Hartley JA, Bailly C (2006) Relation between DNA strand breakage and apopoptic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide. Anti-Cancer Drug 17: 155-164
42. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SPS (2005) Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bioorg Med Chem 13: 5891-5908
43. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878
44. Demarqua D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prevost G, Bigg DCH (2004) BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res 64: 4942-4949
45. Wink M, Alfermann AW, Franke R, Wetterauer B, Distl M, Windhoevel J, Krohn O, Fuss E, Garden H, Mohagheghzadeh A et al (2005) Sustainable bioproduction of phytochemicals by plant in vitro cultures: Anticancer agents. Plant Genet Resour 3: 90-100
46. Asano T, Watase I, Sudo H, Kitajima M, Takayama H, Aimi N, Yamazaki M, Saito K (2004) Camptothecin production by in vitro cultures of Ophiorrhiza liukiuensis and O. kuroiwai. Plant Biotechnol 21: 275-281
47. Puri SC, Verma V, Amna T, Qazi GN, Spiteller M (2005) An endophytic fungus from Nothapodytes foetida that produces camptothecin. J Nat Prod 68: 1717-1719
48. Hsieh HP, Liou JP, Mahindroo N (2005) Pharmaceutical design of antimitotic agents based on combrestratins. Curr Pharm Design 11: 1655-1677
49. Young SL, Chaplin DJ (2004) Combretastatin A4 phosphate: Background and current clinical status. Exp Opin Investig Drugs 13: 1171-1182
50. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Canc 5: 423-435
51. Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA (2006). Medicinal chemistry of combretastatin A4: Present and future directions. J Med Chem 49: 3033-3044
52. Eichler W, Yafai Y, Wiedermann P, Fengler D (2006) Antineovascular agents in the treatment of eye diseases. Curr Pharm Design 12: 2645-2660
53. Hurry JB (1930) The woad plant and its dye. Oxford University Press, London
54. Hoessel R, Leclerc S, Endicott JA, Nobel MEM, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D et al (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1: 60-67
55. Jautelat R, Brumby T, Schäfer M, Briem H, Eisenbrand G, Schwahn S, Krüger M, Lücking U, Prien O, Siemeister G (2005) From the insoluble dye indirubin towards highly active soluble CDK-2 inhibitors. ChemBioChem 6: 531-540
56. Merz KH, Schwahn S, Hippe F, Mühlbeyer S, Jakobs S, Eisenbrand G (2004) Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases. Int J Clin Pharm Th 42: 656-658
57. Sethi G, Ahn KS, Sandur SK, Lin X, Chaturvedi MM, Aggarwal BB (2006) Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kB signaling pathways. J Biol Chem 281: 23425-23435
58. Polychronopoulos P, Magiatis P, Skaltsounis AL, Myrianthopoulos V, Mikros E, Tarricone A, Musacchio A, Roe SM, Pearl L, Leost M et al (2004) Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 47: 935-946
59. Von Tappeiner H, Jesionek A (1903) Therapeutische Versuche mit fluorescierenden Stoffen. Münch Med Wochenschr 47: 2042-2044
60. Agostinis P, Vantieghem A, Merlevede W, de Witte PAM (2002) Hypericin in cancer treatment: More light on the way. Int J Biochem Cell Biol 34: 221-241
61. Ion RM (2000) Porphyrin for tumor destruction in photodynamic therapy. Curr Top Biophys 24: 21-34
62. Vincente MGH (2001) Porphyrin-based sensitizers in the detection and treatment of cancer: Recent progress. Curr Med Chem-Anti-Cancer Agents 1: 175-194
63. Berg K, Selbo PK, Weyergang A, Dietze A, Prasmickaite L, Bonsted A, Enesaeter BØ, Angell-Petersen E, Warloe T, Frandsen N et al (2005) Porphyrin-related photosensitizers for cancer imaging and therapeutic applications. J Microsc 218: 133-147
64. Pandey S, Suresh K, Dubey S, Zheng X, Chen Y, Butt CA, Morgan J, Ciesielski M, Sajjad M, Nabi HA et al (2006) PDT efficiency of phephorbide a analogs upon conjugation with cyclo(RGDfK). Abstract of Papers, 232nd ACS National Meeting, San Francisco CA, USA, 10-14 September 2006
65. Kiesslich T, Krammer B, Plaetzer K (2006) Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr Med Chem 13: 2189-2204
66. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, Bunce CM, Lord JM (2005) PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 106: 1362-1368
67. Hampson P, Wang K, Lord JM (2005) PEP-005. Drug Future 30: 1003-1005
68. Wang X, Matta R, Shen G, Nelin LD, Liu Y (2006) Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J Mol Med 84: 405-415
69. Itokawa H, Wang X, Lee KH (2005) Homoharringtonine and related compounds. Anti-Canc Agents Nat Prod 47-70
70. Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemotherapeutical potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24: 90-114
71. Patocka J (2003) Biologically active pentacyclic triterpenes and their current medicine signification. J Appl Biomed 1: 7-12
72. Fresco P, Borges F, Diniz C, Marques MPM (2006) New insights on the anticancer properties of dietary polyphenols. Med Res Rev 26: 747-766
73. Shukla Y, Pal SK (2004) Dietary cancer chemoprevention: an overview. Int J Hum Genet 5: 265-276
74. Harris DM, Go VLW (2006) How dietary components protect from cancer. In: AB Awad, PG Bradford (eds.) In: Nutrition and cancer prevention, CRC Press, Boca Raton, Florida, 27-58
75. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421
76. D'Incalci M, Steward WP, Gescher AJ (2005) Use of chemopreventive phytochemicals as antineoplastic agents. Lancet Oncol 6: 899-904
77. Singh S, Khar A (2006) Biological effect of curcumin and its role in cancer chemoprevention and therapy. Anti-Cancer Agents Med Chem 6: 259-270
78. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006) Multiple biological activities of curcumin: A short review. Life Sci 78: 2081-2087
79. Signorelli P, Ghidoni R (2005) Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 16: 449-466
80. Jeffery EH, Jarrell J (2001) Cruciferous vegetables and cancer prevention. In: REC Wildman (ed.) In: Handbook of nutraceuticals and functional foods. CRC Press, Boca Raton, Florida, 169-191
81. Park EJ, Pezzuto JM (2002) Botanicals in cancer chemoprevention. Cancer Metast Rev 21: 231-255
82. Greenwald P, Milner JA, Anderson DA, McDonald SS (2002) Micronutrients in cancer chemoprevention. Cancer Metast Rev 21: 217-230
83. Greenwald P (2004) Clinical trials in cancer prevention: Current results and perspectives for the future. J Nutr 134: 3507S-3512S
84. Bemis DL, Katz AE, Buttyan R (2006) Clinical trials of natural products as chemopreventive agents for prostate cancer Expert Opin Inv Drug 15: 1191-1200
85. Wright CW (2005) Plant-derived antimalarial agents: New leads and challenges. Phytochem Rev 4: 55-61
86. Trape JF, Pison G, Spiegel A, Enel C, Rogier C (2002) Combating malaria in Africa. Trends Parasitol 18: 224-230
87. Bray PG, Ward SA, O'Neil PM (2005) Quinolines and artemisinin: Chemistry, biology and history. Curr Top Microbiol 295: 3-38
88. Wright CW (2005) Traditional antimalarials and the development of novel antimalarial drugs. J Ethnoparmacol 100: 67-71
89. Robert A, Benoit-Vical F, Meunier B (2005) The key role of heme to trigger the antimalarial activity of trioxanes. Coordin Chem Rev 249: 1927-1936
90. Posner GH, O'Neil PM (2004) Knowledge of the proposed chemical mechanism of action and cytochrome P450 metabolism of antimalarial trioxane like artemisinin allows rational design of new antimalarial peroxides. Acc Chem Res 37: 397-404
91. Haynes RK, Fugmann B, Stetter J, Rieckmann K, Heilmann H-D, Chan H-W, Cheung MK, Lam W-L, Wong H-N, Croft SL et al (2006) Artemisone - a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed 45: 2082-2088
92. Hofheinz W, Burgin H, Gocke E, Jaquet C, Masciadri R, Schmid G, Stohler H, Urwyler H (1994) Ro 42-1611 (arteflene), a new effective antimalarial: Chemical structure and biological activity. Trop Med Parasitol 45: 261-265
93. Ashley EA, White NJ (2005) Artemisinin-based combinations. Curr Opin Infect Dis 18: 531-536
94. Haynes RK (2006) From artemisinin to new antimalarials: Biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr Top Med Chem 6: 509-537
95. Singh IP, Bharate SB, Bhutani KK (2005) Anti-HIV natural products. Curr Sci 89: 269-290
96. Joshi SP (2002) Plant products as anti-HIV agents. J Med Arom Plant Sci 24: 1006-1023
97. Meadows DC, Gervay-Hague J (2006) Current developments in HIV chemotherapy. ChemMedChem 1: 16-29
98. Cragg GM, Newman DJ (2003) Plants as a source of anti-cancer and anti-HIV agents. Ann Appl Biol 143: 127-133
99. Kashman Y, Gustafson KR, Fuller RW, Cardellina II JH, McMahon JB, Buckheit RW, Hughes SH, Cragg GM, Boyd MR (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 35: 2735-2743
100. Xu Z-Q, Barrow WW, Suling WJ, Westbrook L, Barrow E, Lin Y-M, Flavin MT (2004) Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Bioorg Med Chem. 12: 1199-1207
101. Gustafson KR, Cardellina II JH, McMahon JB, Gulakowski RJ, Ishitoya J, Szallasi Z, Lewin NE, Blumberg PM, Weislow OS, Beutler JA et al (1992) A non-promoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem 35: 1978-1986
102. Hezareh M (2005) Prostratin as a new therapeutic agent targeting HIV viral reservoirs. Drug News Perspect 18: 496-500
103. Williams S, Chen LF, Kwon, H, Fenard D, Bisgrove, D, Verdin, E Greene WC (2004) Prostratin antagonizes HIV latency by activating NF-κB. J Biol Chem 279: 42008-42017
104. Huang L, Kashiwada Y, Cosentino LM, Fan S. Lee K-H (1994) 3′4′-Di-O-(-)-camphanoyl-(+)-cis-khellactone and related compounds: A new class of potent anti-HIV agents. Bioorg Med Chem Lett 4: 593-598
105. Zhang Q, Chen Y, Xia P, Xia Y, Xia Y, Yang ZY, Donglei Y, Morris-Natschke SL, Lee KH (2004) Anti-AIDS agents. Part 62: Anti-HIV activity of 2′substituted 4-methyl-3′4′-di-O-(-)-camphanoyl-(+)-cis- khellactone (4-methyl DCK) analogs. Bioorg Med Chem Lett 14: 5855-5877
106. Yu D, Suzuki M, Xie L, Morris-Natschke SL, Lee KH (2003) Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 23: 322-345
107. Huang L, Yuan X, Yu D, Lee KH, Chen CH (2005) Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. Virology 332: 623-628
108. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, Jiang JB, Janzen WP, Chen IS, Lee K-H (1994) Anti-aids agents, 11. Betulinic acid and platonic acid as anti-HIV principles from Syzygium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 57: 243-247
109. Whelan J (2004) Promising Phase I results against new HIV target. Drug Discov Today 9: 823
110. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM et al (2003) PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 100: 13555-13560
111. Decosterd LA, Parson IC, Gustafson KR, Cardellina II JH, McMahon JB, Cragg GM, Murata Y, Pannell LK, Steiner JR, Clardy J et al (1993) Structure, absolute stereochemistry, and synthesis of conocurvone, a potent, novel HIV-inhibitory naphthoquinone trimer from Conospermum sp. J Am Chem Soc 115: 6673-6679
112. Boyd MR, Hallock YF, Cardellina II JH, Manfredi KP, Blunt JW, McMahon JB, Buckheit Jr RW, Bringmann G, Schaeffer M, Cragg GM et al (1994) Anti-HIV michellamines from Ancistrocladus korupensis. J Med Chem 37: 1740-1745
113. Sorbera, LA, Castaner J, Garcia-Capdevilla L (2005) Celgosivir. Drug Future 30: 545-552
114. Asano N (2003) Glycosidase inhibitors: Update and perspectives on practical use. Glycobiology 13: 93R-104R
115. Ammon HPT (2006) Boswellic acids in chronic inflammatory diseases. Planta Med 72: 1100-1116
116. Singh GB, Atal CK (1986) Pharmacology of an extract of salai guggal ex - Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 18: 407-412
117. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subrananian LR, Ammon HPT (1992) Boswellic acids: Novel, specific nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261: 1143-1146
118. Safayhi H, Sailer ER, Ammon HPT (1995) Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid. Mol Pharmacol 47: 1212-1216
119. Singh GB, Bani S, Singh S (1996) Toxicity and safety of boswellic acids. Phytomedicine 3: 87-90
120. Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HPT, Schabet M, Weller M (1999) Boswellic acids and malignant glioma: Induction of apoptosis but no modulation of drug sensitivity. Brit J Cancer 80: 756-765
121. Winking M, Sarikaya S, Rahmanian A, Jödicke A, Böker DK (2000) Boswellic acids inhibit glioma growth: A new treatment option? J Neuro-Oncol 46: 97-103
122. Lalithakumari K, Krishnaraju AV, Sengupta K, Subbaraju GV (2006) Safety and toxicological evaluation of a novel, standardized 3-O-acetyl-11-keto-β- boswellic acid (AKBA)-enriched Boswellia serrata extract (5-Loxin R). Toxicol Mech Method 16: 199-226
123. Ammon HPT, Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57: 1-7
124. Sharma RA, Gescher AJ, Steward WP (2005) Curcumin: The story so far. Eur J Cancer 41: 1955-1968
125. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB (2006) Curcumine down-regulates expression of cell proliferation and anti-apoptotic and metastatic gene products through suppression of IKB?? kinase and Akt activation. Mol Pharmacol 69: 195-206
126. Shapiro H, Bruck R (2005) Therapeutic potential of curcumin in non-alcoholic steatohepatitis. Nutr Res Rev 18: 212-221
127. Holt PR, Katz S, Kirshoff R (2005) Curcumin therapy in inflammatory bowel disease: A pilot study. Digest Dis Sci 50: 2191-2193
128. Messeguer A, Planells-Cases R, Ferrer-Montiel A (2006) Physiology and pharmacology of the vanilloid receptor. Curr Neuropharmacol 4: 1-15
129. Appendino G, Munoz E, Fiebich BL (2003) TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists. Expert Opin Ther Patents 13: 1825-1837
130. Calixto JB, Kassuya CAL, André E, Ferreira J (2005) Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions. Pharmacol Therapeut 106: 179-208
131. Bley KR (2004) Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Inv Drug 13: 1445-1456
132. Urban L, Campbell EA, Panesar M, Patel S, Chaudhry N, Kane S, Buchheit KH, Sandells B, James IF (2000) In vivo pharmacology of SDZ-249665, a novel, non-pungent capsaicin analogue. Pain 89: 65-74
133. Park NS, Seong CM, Jung YS, Kim WB, Kim SH (2000) DA-5018 (Capsavanil, KR-25018). Drug Future 25: 1131-1137
134. Appendino G, Szallasi A (1997) Euphorbium: Modern research on its active principle resiniferatoxin, revives an ancient medicine. Life Sci 60: 681-696
135. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P (2003) The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304: 56-62
136. Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647
137. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterisation of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613
138. Di Marzo V, Bifulco M, De Petrocelli L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784
139. Lambert DM, Fowler CJ (2005) The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48: 5059-5087
140. Klein TW (2005) cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411
141. Burstein S (2001) Ajulemic acid. Antiinflammatory, oncolytic. Drug Future 26: 324-345
142. Mechoulam R, Sumariwall PF, Feldmann M, Gallily R (2005) Cannabinoids in models of chronic inflammatory conditions. Phytochem Rev 4: 11-18
143. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammtoary, analgesic and leucocyte antiadhesion action. J Med Chem 35: 3135-3141
144. Fride E, Ponde D, Breuer A, Hanus L (2005) Peripheral, but not central effects of cannabidiol derivatives: mediation by CB1 and unidentified receptors. Neuropharmacology 48: 1117-1129
145. San Martin R, Briones R (1999) Industrial uses and sustainable supply of Quillaja saponaria (Rosaceae) saponins. Econ Bot 53: 302-311
146. Kim YJ, Wang P, Navarro-Villalobos M, Rohde BD, Derryberry JM, Gin DY (2006) Synthesis of complex immunostimulants from Quillaja saponaria: Synthesis of the potent clinical immunoadjuvant QS-21Aapi. J Am Chem Soc 128: 11906-11915
147. Kensil CR, Patel U, Lennick M, Marciani D (1991) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol 146: 431-437
148. Kensil CR (1996) Saponins as vaccine adjuvants. Crit Rev Ther Drug 13: 1-55
149. Soltysik S, Wu JY, Recchia J, Wheeler DA, Newmann MJ, Coughlin RT, Kensil CR (1995) Structure/function studies of QS-21 adjuvant: Assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13: 1403-1410
150. Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR (2002) QS-21 structure/function studies: Effect of acylation on adjuvant activity. Vaccine 20: 2808-2815
151. Marciani DJ, Reynolds RC, Pathak AK, Finley-Woodman K, May RD (2003) Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. Vaccine 21: 3961-3971
152. Kersten GFA, Spiekstra A, Beuvery EC, Crommelin DJA (1991) On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochim Biophys Acta 1062: 165-171
153. Kersten GFA, Crommelin DJA (1995) Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta 1241: 117-138
154. Bays H, Stein EA (2003) Pharmacotherapy for dyslipidemia - current therapies and future agents. Expert Opin Pharmaco 4: 1901-1918
155. Urizar NL, Moore DD (2003) Gugulipid: A natural cholesterol-lowering agent. Annu Rev Nutr 23: 303-313
156. Satayavati GV (1988) Gum guggul (Commiphora mukul) - the success story of an ancient insight leading to a modern discovery. Indian J Med Res 87: 327-335
157. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J (2005) Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration. Compl Ther Med 13: 279-290
158. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296: 1703-1706
159. Patel MD, Thompson PD (2006) Phytosterols and vascular disease. Atherosclerosis 186: 12-19
160. Sudhop T, Lütjohann D, von Bergmann K (2005) Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol Ther 105: 333-341
161. Kritchevsky D, Chen SC (2005) Phytosterols - health benefits and potential concerns: A review. Nutr Res 25: 413-428
162. De Melo EB, da Silveira Gomes A, Carvalho I (2006) α- and β-glucosidase inhibitors: Chemical structure and biological activity. Tetrahedron 62: 10277-10302
163. Zou W (2005) C-glycosides and aza-C-glycosides as potential glycosidase and glycosyltransferase inhibitors. Curr Top Med Chem 5: 1363-1391
164. Asano N, Nash RJ, Molyneux RJ, Fleet GWJ (2000) Sugar-mimic glycosidase inhibitors: Natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron-Asymmetr 11: 1645-1680
165. Butters TD, Dwek RA, Platt FM (2005) Imino sugars inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15: 43R-52R
166. Jia W, Gao W, Tang L (2003) Antidiabetic herbal drugs officially approved in China. Phytother Res 17: 1127-1134
167. Grover JK, Yadav S, Vats V (2002) Medicinal plants of India with antidiabetic potential. J Ethnopharmacol 81: 81-100
168. Yeh GY, Eisenberg DM, Kaptschuk TJ, Phillips RS (2003) Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26: 1277-1294
169. Jung M, Park M, Lee HC, Kang YH, Kang ES, Kim SK (2006) Antidiabetic agents from medicinal plants. Curr Med Chem 13: 1203-1218
170. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10: S2-S9
171. Huber A, Stuchbury G, Bürkle A, Burnell J, Münch G (2006) Neuroprotective therapies for Alzheimer's disease. Curr Pharm Design 12: 705-717
172. Francis PT, Nordberg A, Arnold SE (2005) A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 26: 104-111
173. Houghton PJ, Ren Y, Howes MJ (2006). Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep 23: 181-199
174. Wang R, Yan H, Tang XC (2006) Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27: 1-26
175. Kozikowski AP, Tückmantel W (1999) Chemstry, pharmacology, and clinical efficacy of the Chinese nootropic agent huperzine A. Acc Chem Res 32: 641-650
176. Ma X, Gang DR (2004) The Lycopodium alkaloids. Nat Prod Rep 21: 752-772
177. Marco-Contelles J, do Carmo Carreiras M, Rodriguez C, Villaroya M, Garcia AG (2006) Synthesis and pharmacology of galanthamine. Chem Rev 106: 116-133
178. Mukherjee PK, Kumar V, Mal M, Houghton PJ (2007) Acetylcholinesterase inhibitors from plants. Phytomedicine 14: 289-300
179. Zimmermann M, Colchiaghi F, Cattabeni F, Di Luca M (2002) Ginkgo biloba extract: From molecular mechanisms to the treatment of Alzheimer's disease. Cell Mol Biol 48: 613-623
180. Christen Y (2004) Ginkgo biloba and neurodegenerative disorders. Frontiers Biosci 9: 3091-3104
181. Gertz HJ, Kiefer M (2004) Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Design 10: 261-264
182. Andrieu S, Gilette S, Amouyal K, Nourashemi F, Reynish W, Ousset PJ, Albarede JL, Vellas B, Grandjean H (2003) Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 58: 372-377
183. NG TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH (2006) Curry consumption and cognition function in the elderly. Am J Epidemiol 164: 898-906
184. Mancuso C, Scapagnini G, Curro D, Stella AMG, De marco C, Butterfield DA, Calabrese V (2007). Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Frontiers Biosci 12: 1107-1123
185. Lim GP, Chu T, Yang FS, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-8377
186. Yang FS, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2006) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901
187. Langlois N, Gueritte F, Langlois Y, Potier P (1976) Application of a modification of Polonovski reaction to synthesis of vinblastine-type alkaloids. J Am Chem Soc 98: 7017-7024
188. Mishra P, Uniyal GC, Sharma S, Kumar S (2001) Pattern of diversity of morphological and alkaloid yield related traits among periwinkle Catharanthus roseus accessions collected from and around Indian subcontinent. Genet Resour Crop Ev 48: 273-286
189. Schmid W, Balz JP (2005) Cultivation of Ginkgo biloba L. on three continents. Acta Horticult 676: 177-180
190. Suffness M (1993) Taxol - from discovery to therapeutic use. Annu Rep Med Chem 28: 305-314
191. Zhong JJ (2002) Plant cell culture for production of paclitaxel and other taxanes. J Biosci Bioeng 94: 591-599
192. Tabata H (2006) Production of paclitaxel and the related taxanes by cell suspension cultures of Taxus species. Curr Drug Target 7: 453-461
193. Farina V, Brown JD (2006) Tamiflu: the supply problem. Angew Chem Int Ed 45: 2-7
194. Farkya S, Bisaria VS, Srivastava AK (2004) Biotechnological aspects of the production of the anticancer drug podophyllotoxin. Appl Microbiol Biot 65: 504-519
195. Bedir E, Tellez M, Lata H, Khan I, Cushman KE, Moraes RM (2006) Post-harvest and scale up extraction of American mayapple leaves for podophyllotoxin production. Ind Crop Prod 24: 3-7
196. Soeharto DD, Gyllenhaal C, Fong HHS, Xuan LT, Hiep NT, Hung NV, Bich TQ, Southavong B, Sydara K, Pezzuto JM (2004) The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) memorandum of agreement: A model of benefit-sharing arrangement in natural products drug discovery and development. J Nat Prod 67: 294-299
197. Iwu MM (1996) Implementing the biodiversity treaty: How to make international cooperative agreements work. Trends Biotechnol 14: 78-83
198. Anon. (1994) 'Bio-piracy' costs developing world 5 billion a year. Scrip 1980: 19
199. Rausser GC, Small AA (2000) Valuing research leads: Bioprospecting and the conservation of genetic resources. J Polit Econ 108: 173-206
200. Dalton R (2006) Cashing in on the rich coast. Nature 442: 567-569
201. Coley PD, Heller MV, Aizprua R, Arauz B, Flores N, Correa M, Gupta M, Solis PN, Ortega-Barria E, Romero LI et al (2003) Using ecological criteria to design plant collection strategies for drug discovery. Front Ecol Environ 1: 421-428
202. Balandrin MF, Kinghorn AD, Farnsworth NR (1993) Plant-derived natural products in drug discovery and development - an overview. ACS Symp Series 534: 2-12
203. Kinghorn AD (2001) Pharmacognosy in the 21st century. J Pharm Pharmacol 53: 135-148
204. Shu YZ (1998) Recent natural products based drug development: A pharmaceutical industry perspective. J Nat Prod 61: 1053-1071